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Bone morphogenetic proteins (BMPs) constitute a
family of multifunctional growth and differentiation
factors structurally related to transforming growth fac-
tor-b. BMPs were first identified by their osteoinductive
effects, inducing ectopic bone formation when im-
planted in skeletal muscle, and have an important role
as regulators of skeletal development in vivo. In vitro,
BMP-2 is able to transdifferentiate myogenic C2C12
cells into the osteoblastic phenotype. In this report, we
show that the osteoinductive effects of BMP-2 in C2C12
cells are mediated by bone morphogenetic protein re-
ceptor type-IA in combination with both activin recep-
tor type II and bone morphogenetic protein receptor
type II. We also analyzed the expression levels of nuclear
protooncogenes to understand early transcriptional
events induced by BMP-2. We show that junB is an im-
mediate early gene induced by BMP-2 and transforming
growth factor-b. BMP-2 induces transcriptional activa-
tion of JunB expression as early as 30 min after ligand
addition, reaching maximal levels after 90 min. Increase
of JunB mRNA correlates with a higher AP-1 binding
activity. Furthermore, ectopic overexpression of JunB
is sufficient to inhibit expression of myoblast differen-
tiation markers in C2C12 cells. These data, taken to-
gether, show the involvement of JunB in the early steps
of inhibition of myogenic differentiation induced by
transforming growth factor-b family members.
During mammalian development, pluripotent mesenchymal
cells give rise to several specialized cell types, including cells
with myogenic, osteogenic, or adipogenic potential. This differ-
entiation process consists of at least two stages. In the first step
or commitment, upon certain stimuli, undifferentiated cells
become committed to a particular lineage. Later, during termi-
nal differentiation, cells acquire specific phenotypes by ex-
pressing genes encoding a set of proteins unique to a certain
type of cells. The best known example of master genes govern-
ing cell fate are the family of myogenic basic helix-loop-helix
(bHLH)1 transcription factors (1). In muscle, the bHLH factors
MyoD and Myf-5 play a role in lineage determination, whereas
myogenin and MRF4 appear soon thereafter to execute the
differentiation program (1–2). Other examples of such factors
are the peroxisome proliferator-activated receptor g and
CCAAT/enhancer-binding protein family members, which con-
trol adipocyte differentiation or the transcription factor Cbfa1,
recently found as an activator of osteoblast differentiation (3–
5). The fact that ectopic expression of each these factors is
sufficient to induce a unique differentiation program or even to
transdifferentiate cells from other lineages emphasizes their
key function (6–8).
Each specific cell commitment and differentiation program is
ultimately controlled by signals and regulatory pathways that
converge to activate a small number of transcription factors.
These mechanisms involve cell-cell and cell-matrix interac-
tions, as well as extracellular diffusible factors. Among the
latter, bone morphogenetic proteins (BMPs) have been shown
to be regulators of skeletal development (9). They were origi-
nally identified by their osteoinductive effects, inducing ectopic
bone formation when exogenously implanted in rat or mouse
muscle (10). Furthermore, knock-out mice showed marked
skeletal defects (11–14), and they are expressed in the embryo
at sites of cartilage and bone formation (15). BMP-2/4 also play
a role in inductive interactions during early development, reg-
ulating dorso-ventral patterning and mesoderm induction (16).
In addition to their function during morphogenesis and deter-
mination of the body axis, BMPs are also involved in later
stages of development. BMPs not only stimulate maturation of
osteoblast precursor cells, they also convert the differentiation
pathway of myoblastic cells into the osteoblast lineage (17).
BMPs belong to the transforming growth factor-b (TGF-b)
superfamily encompassing TGF-bs, activins, and Mullerian in-
hibiting substance. BMPs and other members of the TGF-b
superfamily exert their biological function by interacting with
two types of related transmembrane serine/threonine kinase
receptors, known as type I and type II (18). For both TGF-b and
activin, receptor activation requires binding of ligand to the
type II receptor, which then recruits and phosphorylates the
type I receptor (19). Phosphorylation on the GS region activates
the kinase activity of the type I receptor, which propagates the
signal to downstream substrates (19–20). The BMP receptor
system is somewhat different. They also require heteromeric
complex formation for signaling, but, unlike TGF-b or activin,
BMP type I receptors are able to bind the factor without coex-
pression of type II receptors; however, both together achieve
high affinity binding (21–23). Downstream signaling by these
receptors is mediated by the recently identified family of Smad
proteins (18, 24). In response to receptor activation, Smad
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Ministerio de Educación y Ciencia (to T. L.). The costs of publication of
this article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
‡ To whom correspondence should be addressed. Tel.: 34-3-4024281;
Fax: 34-3-4024213; E-mail: fventura@bellvitge.bvg.ub.es.
1 The abbreviations used are: bHLH, basic helix-loop-helix; BMP,
bone morphogenetic protein; TGF-b, transforming growth factor-b;
BMPR-I, bone morphogenetic protein receptor type I; TbR-I, transform-
ing growth factor-b receptor type I; ActR-II, activin receptor type II;
BMPR-II, bone morphogenetic protein receptor type II; PCR, polymer-
ase chain reaction; CAT, chloramphenicol acetyltransferase; PAGE,
polyacrylamide gel electrophoresis; HA, hemagglutinin; DMEM, Dul-
becco’s modified Eagle’s medium.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 273, No. 1, Issue of January 2, pp. 537–543, 1998
© 1998 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 537
This is an Open Access article under the CC BY license.
proteins become phosphorylated at their carboxyl termini and
translocate into the nucleus (25–27). Recent results support the
notion that distinct Smad family members transduce signaling
from specific receptor combinations. Smad1 is a BMP signal
transducer, and the closely related Smad2 and Smad3 are
TGF-b/activin signal transducers. Smad4/DPC4, originally
found as a gene mutated in pancreatic carcinomas (28), func-
tions as a shared partner, which hetero-oligomerizes with all
other Smads upon phosphorylation (29). Once into the nucleus,
Smad complexes probably exert a direct role in transcriptional
control. Consistent with this function, transcriptional activity
of various Smad proteins and association of Smad2 with the
DNA-binding protein FAST1 have recently been shown (30).
Although the molecular mechanisms involved in BMP sig-
naling are beginning to emerge, the precise BMP receptor
combinations as well as early transcriptional events that me-
diate the osteogenic differentiation effects of BMP in muscular
tissues have remained elusive. Here, we report that the os-
teoinductive response to BMP-2 in C2C12 cells is mediated by
the type I receptor BMPR-IA in combination with both type II
receptors BMPR-II and ActR-II. Additionally, to understand
early events induced by BMP-2, we analyzed the expression
level of nuclear protooncogenes. Results presented here indi-
cate that junB is an immediate early gene transcriptionally
induced by BMP-2. Moreover, ectopic overexpression of JunB is
sufficient to inhibit expression of myogenic markers on C2C12
cells. Therefore, these data suggest the involvement of JunB in
the inhibition of myogenic differentiation induced by BMP-2.
EXPERIMENTAL PROCEDURES
Plasmids, Cell Lines, and Transfections—a-Actin and a-acetylcho-
line receptor promoter regions fused to a CAT reporter were kindly
provided by Dr. Kocniezcny (Purdue University; West Lafayette, IN)
(31). TbR-IHA and ActR-IHA vectors have been described previously (32).
BMPR-IAHA construct containing the hemagglutinin (HA) epitope at
the carboxyl terminus was generated by PCR. A full-length JunB cDNA
was subcloned into pCDNA3 for mammalian expression. A 3-kilobase
mouse JunB promoter fused in a CAT reporter (JB3000CAT) was kindly
provided by Dr. Nakajima (Osaka University; Osaka, Japan). C2C12
were cultured in DMEM supplemented with 20% fetal bovine serum
and transiently transfected with the indicated vectors by the calcium
phosphate method (33). Cell lines COS-1 and R1B/L17 were cultured
and transiently transfected with the indicated vectors as described
previously (32).
Immunofluorescence—C2C12 cells were grown on coverslips and
treated with BMP-2 (Genetics Institute, Cambridge, MA) or TGF-b1
(Sigma) for 3 days in DMEM supplemented with 2% inactivated horse
serum. Cells were fixed in 4% paraformaldehyde and processed as
described in Ref. 34, using rabbit anti- myosin antiserum as primary
antibody (1/100 dilution) (Sigma) and Texas red-labeled anti-rabbit
antibody as secondary antibody (Amersham Life Science Inc.).
Alkaline Phosphatase and CAT Assays—Alkaline phosphatase was
assayed as follows. Cells were washed with phosphate-buffered saline
and lysed in 50 mM Tris-HCl, 0.5% Nonidet P-40, pH 7.5. Cell lysates
were incubated in a buffer containing 0.1 M glycylglycine, 5 mM MgCl2,
and 10 mM p-nitrophenyl phosphate, pH 9.5. The reaction was stopped
with 0.5 M NaOH, and absorbance was measured at 405 nm. CAT
activity from transiently transfected cells was measured as described in
Ref. 33.
RNA Preparation and Northern Blots—Total RNA was extracted
from C2C12 cells according to the Chomczynski method (33). Northern
analysis was done as described in Ref. 33.
Affinity Labeling in Vivo and in Vitro—Receptor affinity labeling
assays in vivo were performed as described in Ref. 32. For in vitro
affinity labeling, cell extracts from COS-1 cells expressing epitope-
tagged receptors were immunoprecipitated using anti-HA antibody
(12CA5 Babco) and protein A-Sepharose (Pharmacia Biotech Inc.). Im-
munoprecipitates were washed five times in 50 mM Tris-HCl, 150 mM
NaCl, 0.5% Triton X-100, pH 7.5. After washing twice in Krebs-Ringer
Hepes buffer, bound receptors were incubated with 125I-BMP-2 for 3 h
at 4 °C, followed by four washes in the same buffer. Receptors were
cross-linked to bound ligand with disuccinimidyl suberate (Pierce) for
15 min, washed twice, and subjected to SDS-PAGE and
autoradiography.
Immunoprecipitations—Antibodies against ActR-I, BMPR-IA, and
BMPR-IB were kindly provided by Dr. P. ten Dijke (Ludwig Institute for
Cancer Research, Uppsala, Sweden) (35). Antibodies against ActR-II
were kindly provided by Dr. W. Vale (The Salk Institute, La Jolla, CA)
(36). Affinity-labeled receptors from C2C12 cells were solubilized in 50
mM Tris-HCl, 150 mM NaCl, 0.5% Triton X-100, pH 7.5. Cell extracts,
clarified by centrifugation, were incubated with each antibody for 1 h at
4 °C, followed by incubation with protein A-Sepharose for another 1 h.
Bound receptors were then washed five times in solubilization buffer,
and subjected to SDS-PAGE and autoradiography.
Electrophoretic Mobility Shift Assays—Nuclear extracts were pre-
pared by the method of Andrews and Faller (33). Pelleted cells were
resuspended in 400 ml of cold Buffer A (10 mM Hepes-KOH, pH 7.9 at
4 °C, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM dithiothreitol, 0.2 mM phenyl-
methylsulfonyl fluoride) by flicking the tube. After a 10-min incubation
on ice, cells were vortexed for 10 s and then centrifuged. The pellet was
resuspended in 20–100 ml of cold buffer C (20 mM Hepes-KOH, pH 7.9,
25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride) and incubated on
ice for 20 min for high salt extraction. Cellular debris was removed by
centrifugation for 2 min, and the supernatant fraction were stored at
270 °C. The protein content was determined using the Bradford protein
concentration assay (Bio-Rad) with bovine serum albumin as standard.
The AP-1 oligonucleotide 59-CGCTTGATGAGTCAGCCGGAA-39 (Pro-
mega) was labeled with [g-32P]ATP and T4 polynucleotide kinase.
Four micrograms of the nuclear protein were diluted to a final vol-
ume of 20 ml in a reaction mixture containing 20 mM Tris, pH 7.9, 50 mM
NaCl, 10% glycerol, 0.1 mM dithiothreitol, and 1.25 mg of poly(dI-dC);
0.2 pmol of labeled probe (4 3 104 cpm) was added after 15 min. After
an additional 30-min incubation at room temperature, the reaction
mixture was loaded onto a 6% polyacrylamide gel, 0.25 3 TBE, and 4%
glycerol, and resolved at 20 mA for 2.5 h. Gels were dried and autora-
diographed at 280 °C.
RESULTS
C2C12 myoblasts constitute an in vitro model system to
study the ability of BMPs to alter cell lineage from the myo-
genic to the osteogenic phenotype. C2C12 cells differentiate
into multinucleated myotubes when concentration of serum is
reduced from 20% to 2%. BMP-2 inhibits myotube formation,
inducing osteoblastic markers such as alkaline phosphatase
activity or osteocalcin production (17). Treatment with 1 nM
BMP-2 or 1 nM TGF-b completely inhibited myotube formation
and myosin expression on C2C12 cells exposed to differen-
tiation media (Fig. 1A). This BMP2-dependent inhibition of
myogenic differentiation could be also seen using reporter
constructs containing muscle-specific promoter regions of myo-
genic markers such as a-actin or a-acetylcholine receptor. Ad-
dition of 1 nM BMP-2 to cells treated with differentiation media
inhibited 50–70% of their CAT reporter activity (Fig. 1B). In-
hibition of reporter expression is not a general transcriptional
effect of BMP-2 since expression from constitutive promoters
did not show any change (data not shown). C2C12 cells express
extremely low levels of alkaline phosphatase and other osteo-
blastic markers when cultured both in proliferative or differ-
entiation media. Time-course studies show that, of all the
TGF-b superfamily members tested, only BMP-2 is able to
stimulate alkaline phosphatase expression, beginning to ap-
pear within 2 days, and increasing until day 4 (Fig. 1C). These
data indicate that different members of of the TGF-b super-
family have distinct biological effects on selection of C2C12
terminal differentiation.
We analyzed the expression and binding affinity of distinct
activin and BMP receptors in C2C12 cells to determine which
receptor combinations are involved in osteogenic BMP re-
sponses. Northern analysis indicates that C2C12 cells express
BMPR-II and ActR-II as activin/BMP type II receptors and
ActR-I and BMPR-IA as type I receptors (Fig. 2A). In contrast,
both ActR-IIB and BMPR-IB were expressed below detection
limits of either Northern or reverse transcription-PCR analysis
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(data not shown).
We also tested binding of BMP-2 to the endogenous receptors
expressed in C2C12 cells. Immunoprecipitation of the cross-
linked receptor complexes using antiserum against BMPR-IA
gave a strong signal of about 75 kDa (Fig. 2B). A labeled band
could be seen in immunoprecipitates using an antiserum
against ActR-II. In addition, a weak signal was detected when
antiserum against BMPR-IB was used. This signal could be
generated by a small number of BMPR-IB receptor mRNA that
could not be detected by reverse transcription-PCR. Alterna-
tively, since BMPR-IB antibody was raised against peptides
derived from its juxtamembrane region (35), and BMPR-IA and
-IB have closely related juxtamembrane regions, it is likely
that the antibody against BMPR-IB cross-reacts with small
amounts of BMPR-IA. Although it has been reported that
ActR-I is able to bind BMP-2/4 when overexpressed in COS-1
cells (23), using the same immunoprecipitation approach, we
could not detect any BMP-2 binding to ActR-I at physiological
receptor levels.
Some cross-linking studies showed that when transiently
transfected, type I receptors for BMP are capable of binding to
BMP2/4 without coexpression of the type II receptor (21, 23). To
confirm these data and exclude the possibility that endogenous
type II receptor expressed in these cells could allow binding to
type I receptors, we analyzed the ability of distinct purified
type I receptors to bind BMP-2 in vitro. Epitope-tagged BMP-2
receptors expressed in COS cells were immunopurified and
subjected sequentially to binding and cross-linking to 125I-
BMP-2. This binding assay showed specific binding of the li-
gand to BMPR-IA compared with control lanes derived from
mock-transfected cells or cells transfected with transforming
growth factor-b receptor type I (TbR-I), which is unable to bind
BMP-2. In agreement with the in vivo assays, purified ActR-I
was also unable to bind BMP-2 by itself (Fig. 2C). Altogether,
these results suggest that the major receptor complexes in-
volved in osteogenic responses of BMP-2 are those including
BMPR-IA in combination with ActR-II and probably BMPR-II.
TGF-b has been shown to modulate expression of several
nuclear protooncogenes in epithelial and fibroblastic cells (37–
38). In addition, knock-out mice for transcription factors in-
volved in AP-1 function, such as c-Fos or ATF2, exhibited
profound defects in bone formation (39–40). These two lines of
evidence led us to investigate the expression levels of nuclear
protooncogenes to understand early transcriptional events in
myogenic/osteogenic transdifferentiation processes induced by
BMP-2. RNAs from C2C12 cells cultured with or without 1 nM
BMP-2 in differentiation media were analyzed by Northern
blotting. As shown in Fig. 3, expression of c-jun, junD, or c-myc
was not significantly modified at any time point, either with or
without ligand addition. However, 1 nM BMP-2 transiently
increased JunB mRNA. Induction of JunB is detected as early
FIG. 1. Effects of BMP-2 and TGF-b
in C2C12 differentiation. A, immuno-
fluorescence analysis using anti-myosin
antibodies of C2C12 cells cultured for 3
days in differentiation media in the ab-
sence (left panel), with 1 nM BMP-2 (mid-
dle panel), or with 1 nM TGF-b (right
panel). B, BMP-2 blocks expression of
myogenic markers. C2C12 cells were
transiently transfected with a-actin CAT
or a-acetylcholine receptor (Ach R)-CAT.
24 h after transfection, cells were incu-
bated with differentiation media in the
absence (open bars) or the presence of 1
nM BMP-2 (solid bars), and CAT activity
was measured 2 days later. Results are
the mean 6 S.E. of three separate exper-
iments. C, time-course assay of alkaline
phosphatase activity of C2C12 cells
treated as in A. Results are the mean 6
S.E. of three experiments.
FIG. 2. Expression and binding abilities of receptors for BMP-2
in C2C12 cells. A, Northern blots of RNA (20 mg) obtained from
undifferentiated C2C12 cells were sequentially hybridized with cDNA
probes for known receptors for BMPs. RNA size for each receptor is
indicated by arrows. B, affinity labeling of different BMP-2 receptors
expressed in C2C12. C2C12 cells were affinity-labeled in vivo as de-
scribed under “Experimental Procedures.” Equal amounts of cell lysates
were immunoprecipitated with the indicated antibodies, subjected to
SDS-PAGE and autoradiography. C, receptors expressed in COS-1 cells
transfected with different type I receptors or with vector alone were
immunopurified by sequential incubation with anti-HA antibody and
protein A-Sepharose. Purified receptors were affinity-labeled in vitro
with 125I-BMP-2, and binding was visualized by SDS-PAGE and
autoradiography.
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as 30 min after BMP-2 addition, reaching maximal (9-fold over
control levels) levels after 90 min and decreasing thereafter.
Interestingly, we also detected a sharp induction of c-fos tran-
scription at 30 min, followed by a rapid decline to control levels.
Nevertheless, this induction was observed both in BMP-2-
treated and untreated cells, suggesting this effect was likely
due to media replacement and is not a consequence of BMP-2
addition.
We next assessed whether induction of JunB is dependent on
new protein synthesis. C2C12 cells were treated with BMP-2
for 90 min, together with the protein synthesis inhibitor, cyclo-
heximide (10 mg/ml), or the RNA synthesis inhibitor, actinomy-
cin D (1 mg/ml). Northern analysis revealed an even higher
induction of JunB mRNA in the presence of cycloheximide and
a complete block of induction when actinomycin D was added
(Fig. 4). We also tested the effects of other members of the
TGF-b superfamily on JunB mRNA levels. TGF-b at 1 nM
strongly induced JunB mRNA, whereas no significant induc-
tion was detected in RNA from C2C12 cells treated with 1 nM
activin A (Fig. 4).
Transient cell transfections with a JunB promoter/CAT re-
porter gene construct were performed to confirm whether
BMP-2 and TGF-b regulate JunB mRNA steady state levels
through modulation of its transcription rate. R1B/L17 clone,
which is unresponsive to TGF-b due to mutations at its recep-
tor type I (32), and C2C12 cells were transfected with a CAT
construct containing a 3-kilobase proximal region of mouse
JunB promoter and treated with BMP-2 or TGF-b both at 1 nM.
Assay of CAT activity after 16 h of incubation indicated that
both factors induced promoter activity 2–3-fold as compared
with control cultures in C2C12 cells, whereas only BMP-2 was
able to stimulate CAT activity in L17 cells (Fig. 5). Thus, these
results indicate that the enhancement of junB gene expression
in myogenic cells does not require protein synthesis and is
mediated, at least in part, by modulation of its promoter
activity.
AP-1 is a collective term referring to homo- and het-
erodimeric transcription factors composed of members of the
Jun, Fos, or ATF families that bind to a common DNA site
known as the AP-1 binding site. Distinct combinations of AP-1
factors regulate different target genes and thus execute dis-
tinct biological functions (41). We tested if higher expression
levels of JunB mRNA induced by BMP-2 correlate with higher
FIG. 4. Effect of different TGF-b family members on JunB tran-
scriptional induction. C2C12 cells were treated for 90 min with 1 nM
of the indicated factors, and some cultures also received cycloheximide
(Chx) (10 mg/ml) or actinomycin-D (Act D) (1 mg/ml). Total RNA was
extracted, and JunB expression was measured by Northern blot
analysis.
FIG. 3. Effect of BMP-2 on gene expression of nuclear protooncogenes. Cultured C2C12 cells were induced to differentiate in the presence
or absence of BMP-2. Total RNA was extracted at different time points, analyzed by Northern blotting, and hybridized with the indicated cDNA
probes. A, analysis of expression of cells treated with BMP-2 for different times. B, densitometric analysis of signals detected on Northern blots
of cells treated with BMP-2 relative to cells treated only with differentiation media. Signals were normalized using expression of 18 S rRNA as
control. To indicate the specific effects of BMP-2 on gene expression, results are expressed as -fold induction relative to cells treated for the same
period of time with only differentiation media. Results are the mean of two separate experiments.
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AP-1 function. Gel mobility shifts were performed with a ra-
diolabeled AP-1 consensus oligonucleotide incubated in the
presence of nuclear extracts from cells treated with or without
1 nM BMP-2 at different times. As shown in Fig. 6, we obtained
a single shifted band. This band was completely competed with
a 50-fold molar excess of unlabeled probe (data not shown).
There was a binding increase in extracts from cells treated or
not with factor for 1 h. This BMP-independent increase is likely
to be due to the strong activation of c-Fos transcription, seen at
30 min in Fig. 3, since it has been described that c-Fos can be
rate-limiting in the formation of heterodimers with the other
AP-1 members (41). At later times, the intensity of the shifted
band progressively increased in extracts from cells treated with
BMP-2 in respect to their control counterparts. Preincubation
of the extracts with antibody against JunB partly abrogates the
binding, further suggesting the involvement of JunB in these
AP-1 complexes (Fig. 6). These data suggest that induction of
JunB results in formation of transcriptionally active AP-1 com-
plexes specific for JunB-regulated genes.
Whereas both BMP-2 and TGF-b induce JunB transcription
and inhibit myogenic differentiation of C2C12 cells, only
BMP-2 is able to transdifferentiate these cells to the osteoblas-
tic lineage. Thus, we analyzed the relationship between JunB
expression and myogenic differentiation. We used regulatory
sequences of a-actin and a-acetylcholine receptor genes fused
to a CAT reporter gene. These enhancers contain binding sites
for myogenin and MyoD that are strictly muscle-specific (31).
Fig. 7 shows that CAT activities were induced 2–4-fold in
C2C12 cells transfected with those reporters when shifted to
differentiation media for 3 days. These transcriptional activa-
tions were efficiently blocked by addition of both BMP-2 or
TGF-b. More interestingly, when cotransfection assays were
performed with a JunB expression vector, transactivation of
both reporters by differentiation media was completely sup-
pressed. No effects were seen using SV40-b-galactosidase as
reporter or when other unrelated genes were cotransfected
with the CAT reporters (data not shown). Thus, we conclude
that induction of JunB is sufficient and could be, at least partly,
responsible of the inhibition of myogenic differentiation of
C2C12 cells by BMP-2 and TGF-b.
DISCUSSION
Our results show that the ability of BMP-2 to transdifferen-
tiate myogenic cells to the osteoblastic lineage is mediated by
pathways activated by BMPR-IA. We also demonstrate that
activation of these pathways lead to early transcriptional acti-
vation of junB gene expression with a concomitant increase in
JunB-dependent AP-1 binding activity. TGF-b, another mem-
ber of the TGF-b superfamily, shares with BMP-2 both the
ability to inhibit myogenesis and to activate transcription of
JunB. On the basis of this evidence and the observation that
ectopic expression of JunB in myogenic precursor cells is suf-
ficient to inhibit myogenic differentiation, we propose that the
induction of JunB has an important role in the control of
myogenic differentiation by BMP-2 and TGF-b.
During the process of ectopic bone formation, after bone-
inducing factors are implanted into muscular tissues, these
factors appear to alter the differentiation of muscle cells
around the implantation sites (9). BMPs have been shown to be
potent bone inducers in vivo (9–10). Although related factors
failed to induce ectopic bone formation, some of them are able
FIG. 5. Effect of BMP-2 and TGF-b on JunB promoter activity.
R1B/L17 cells, deficient in TGF-b receptor type I, and C2C12 cells were
transfected with JunB promoter-CAT (JB3000CAT) as described under
“Experimental Procedures.” Two days later, cells were incubated with
the indicated factors at 1 nM in DMEM supplemented with 0.1% serum.
CAT activity was assayed 16–20 h later. The upper panel shows repre-
sentative results; in the lower panel, results, presented as relative
promoter activity, are the means 6 S.E. of three separate transfections.
FIG. 6. AP-1 binding activity is increased in C2C12 cells
treated with BMP-2. Nuclear extracts were obtained from C2C12 cells
treated with or without BMP-2 in differentiation media for different
times. Extracts were incubated with 32P-labeled AP-1 consensus oligo-
nucleotide, and, when indicated, JunB antibody (a-junB) was added.
Binding mixtures were separated by nondenaturing PAGE and sub-
jected to autoradiography.
FIG. 7. JunB is sufficient to inhibit myogenic differentiation of
C2C12 cells. C2C12 cells were cotransfected with myogenic reporters
in combination with JunB expression vector (jun B) or vector alone
(Mock). The day after transfection, medium was changed to DMEM plus
20% serum (open bars), DMEM plus 2% serum (solid bars), DMEM plus
2% serum with 1 nM BMP-2 (dashed bars), or DMEM plus 2% serum
with 1 nM TGF-b (gray bars). Two days later, cells were harvested and
CAT activity assayed. All values are reported as -fold induction relative
to the CAT level of cells grown in proliferative media, referred as 1.
Results are expressed as mean 6 S.E. of four separate transfections.
FBS, fetal bovine serum; AchR, acetylcholine receptor.
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to act as negative regulators of muscle cell development. In this
regard, it has recently been shown that knock-out mice for
GDF-8, a member of the TGF-b superfamily, have 2–3-fold
increased body mass (42). In the present study, we show that
the TGF-b-related factors studied differ in their transdifferen-
tiation effects in C2C12 cells. Whereas, in agreement with Ref.
17, BMP-2 both inhibits myogenesis and activates osteogene-
sis, TGF-b is only capable of inhibit myogenesis (Fig. 1). The
above data suggest that osteogenic effects are elicited by a
unique signaling pathway initiated by BMP-2.
BMPR-IA Is the Main Receptor for BMP-2 in C2C12 Cells—
BMP signaling at the plasma membrane is mediated by a
subset of transmembrane serine/threonine kinase receptors
(18). However, a certain redundancy in the ligand binding of
the type I receptors has been reported (18, 21–23). For this
reason, the assignment of precise receptor combinations that
mediate each activin or BMP response remains tentative. For
example, BMP-4 binds to BMPR-IA and BMPR-IB, whereas
BMP-7 binds to BMPR-IB and less efficiently to BMPR-IA (21).
Both BMP-2 and BMP-7 can also bind to one of the activin type
I receptors, ActR-I, in the presence of a suitable receptor type II
(23). In respect to type II receptors, BMPR-II has been shown to
bind BMP-2, -4, and -7 and is required for signaling in combi-
nation with certain type I receptors (22–23). Additionally,
BMP-7 has been shown to bind to ActR-II/ActR-I complexes,
signaling certain activin-like effects (43). The present identifi-
cation of ActR-II as a BMP-2 binding receptor at physiological
expression levels further extends the notion of versatility in
this receptor system. Our conclusion that the osteogenic re-
sponses induced by BMP-2 in C2C12 cells arise from activation
of BMPR-IA rests on several lines of evidence. First, immuno-
precipitation assays show that BMPR-IA is the expressed re-
ceptor on C2C12 cells (BMPR-IB is not expressed or expressed
at very low levels) with higher binding affinity for BMP-2 (Fig.
2). Second, although required for signaling, its ability to bind
BMP-2 is independent of the presence of a type II receptor,
suggesting that in the cellular context it could combine with
both BMPR-II and ActR-II acting as activating receptors. Fur-
thermore, constitutively active BMPR-IA is sufficient to medi-
ate osteoinductive responses in chicken wing development (44),
suggesting that, as with other TGF-b superfamily receptors,
signaling depends on the specificity of receptor type I kinase.
junB Is an Immediate Early Gene Induced by BMP-2—De-
velopmental studies performed in vitro and in vivo implicate
the Fos and Jun family of transcription factors in the regula-
tion of bone tissue formation (39–41). Here we show that, from
all AP-1 transcription factors studied, only JunB is highly
induced at early times after BMP-2 or TGF-b addition (Fig. 3).
Regulation of the steady-state levels of JunB is likely to be due
to regulation of its transcription rate since addition of actino-
mycin D completely blocks induction of its mRNA by BMP-2.
Furthermore, BMP-2 and TGF-b are able to induce expression
from an heterologous reporter construct. R1B/L17 cells lack
functional type I receptors for TGF-b, but they have receptors
for BMPs (21–22). Thus, the fact that, in these cells, only
BMP-2 activated reporter expression indicates that the signal
transduction elicited by BMP-2 and TGF-b are initiated by
distinct subsets of receptors at the cell membrane, that at some
later point, would converge in this specific JunB transcrip-
tional response.
Since induction of the junB gene is not affected by the protein
synthesis inhibitor cycloheximide, it would appear that trans-
acting factors required for transcription preexist in the cell.
The Smad family of proteins are the only known mediators of
the TGF-b superfamily signaling. In response to receptor acti-
vation, Smad proteins become phosphorylated and translocate
into the nucleus where is likely they activate transcription by
interacting FAST-like DNA-binding proteins (18, 24–27, 29–
30). Time-course assays showed that BMPR-IA-dependent
Smad1 phosphorylation and nuclear translocation begins
10–20 min after BMP-2 addition and remains elevated for up to
2 h (25), which is in agreement with the profile of JunB mRNA
induction by BMP-2. Smad1 is expressed in C2C12 cells, and
its mRNA levels do not change after BMP-2 addition (data not
shown). Taken together, these data support the attractive pos-
sibility that the Smad family may be the direct mediators of
this JunB transcriptional activation. If this is true, two alter-
native possibilities could be envisaged. One is that the JunB
promoter could contain distinct response elements for BMP-2
and TGF-b; alternatively, since phosphorylation of Smad fam-
ily members by different receptors has been described to be
specific (26–27), downstream signaling components could have
overlapping specificities.
Ectopic Expression of JunB Is Sufficient to Inhibit Myogenic
Differentiation—Several studies reported differences in the
pattern of expression and response to stimuli between Jun
family members (41). In addition, considerable differences in
their transactivation and transforming activities have been
reported (38, 41, 45–46); c-Jun is an effective activator of
human collagenase and synthetic promoters containing a sin-
gle 12-O-tetradecanoylphorbol-13-acetate response element,
whereas JunB transactivates promoters with multiple 12-O-
tetradecanoylphorbol-13-acetate response elements (46). In ad-
dition, c-Jun2/2 mouse showed embryonic lethality, further
suggesting Jun family members have non-equivalent tran-
scriptional functions (39–40). In addition, overexpression of
JunB has been shown to counteract activation of c-Jun-respon-
sive genes, suggesting a role for JunB as a negative regulator of
c-Jun (45, 46). Protein interaction assays showed, in the ab-
sence of c-Fos, preferential formation of c-Jun/JunB het-
erodimers that have decreased DNA binding activity in respect
to their homodimeric counterparts, whereas, in the presence of
c-Fos, preferential formation of JunB/c-Fos heterodimers
should contribute to AP-1 activity (45). Therefore, modification
in the relative levels of Fos and Jun family members by extra-
cellular factors, such as BMP-2 and TGF-b, would result in the
presence of a specific subset of AP-1 dimers with altered tran-
scriptional activity. This hypothesis has been demonstrated in
the differential regulation of collagenase transcription by cell-
specific induction of JunB or c-Jun and could also be the case in
the C2C12 model presented here since ectopic overexpression
of JunB, altering the c-Jun/JunB ratio within the cell, is suffi-
cient to mimic inhibition of myogenic differentiation by BMP-2
and TGF-b.
Evidence points to inhibition of myogenic bHLH transcrip-
tional activity as the key event in inhibition of myogenic dif-
ferentiation by TGF-b family members. Not only do BMP-2 and
TGF-b inhibit expression of myogenic factors in myoblasts (47),
they also inhibit terminal differentiation of cells overexpress-
ing myogenin without altering their DNA binding ability (47,
48). These results suggest that the myogenic activity of these
transcription factors is also inhibited at posttranscriptional
levels. Id-1 antagonizes myogenic factor binding to the E-boxes
in muscle-specific promoters (49), and its expression is in-
creased by BMP-2 (50). In addition, besides its own transcrip-
tional activity, increased levels of JunB also interferes with
bHLH function (51). It has been shown that MyoD directly
interacts with Jun family members (52). Additionally, both the
MyoD and Jun family of proteins require coactivation by p300/
CBP (41, 53) and, since availability of these coactivators could
be rate-limiting, a competition between distinct transcription
factors could take place within the cell.
JunB Is Involved in the Inhibition of Myogenesis by BMP-2542
In conclusion, the present results show that junB is an im-
mediate early gene induced by BMP-2 through a pathway
initiated by BMPR-IA, and they also implicate JunB as a factor
involved in some of the mechanisms by which TGF-b family
members inhibit myogenic bHLH transcriptional activity. Fur-
ther research is needed to clarify the molecular mechanisms of
JunB-mediated inhibition of myogenesis and to analyze the
pathways that lead to transcriptional activation of JunB ex-
pression induced by BMP-2.
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C. Harvey, S. Konieczny, J. Massagué, K. Nakajima, G. Pons, A. Tauler,
P. ten Dijke, and W. W. Vale for discussion and gifts of plasmids,
antibodies, and reagents. We also thank the Genetics Institute for
recombinant BMP-2.
REFERENCES
1. Molkentin, J. D., and Olson, E. N. (1996) Curr. Opin. Genet. Dev. 6, 445–453
2. Rawls, A., and Olson, E. N. (1997) Cell 89, 5–8
3. Spiegelman, B. M., and Flier, J. S. (1996) Cell 87, 377–389
4. Brun, R. P., Kim, J. B., Hu, E., Altiok, S., and Spiegelman, B. M. (1996) Curr.
Opin. Cell Biol. 8, 826–832
5. Rodan, G. A., and Harada, S. (1997) Cell 89, 677–680
6. Davis, R. L., Weintraub, H., and Lassar, A. B. (1987) Cell 51, 987–1000
7. Hu, E., Tontonoz, P., and Spiegelman, B. M. (1995) Proc. Natl. Acad. Sci.
U. S. A. 92, 9856–9860
8. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, G. (1997) Cell 89,
747–754
9. Reddi, A. H. (1997) Cytokine Growth Factor Rev. 8, 11–20
10. Wozney, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz,
R. W., Hewick, R. M., and Wang, E. (1988) Science 242, 1528–1534
11. Kingsley, D. M., Bland, A. E., Grubber, J. M., Marker, P. C., Russell, L. B.,
Copeland, N. G., and Jenkins, N. A. (1992) Cell 71, 399–410
12. Storm, E. E., Huynh, T. V., Copeland, N. G., Jenkins, N. A., Kingsley, D. M.,
and Lee, S.-J. (1994) Nature 368, 639–643
13. Dudley, A. T., Lyons, K. M., and Robertson, E. J. (1995) Genes Dev. 9,
2795–2807
14. Luo, G., Hoffmann, C., Bronckers, A. L. J. J., Sohicki, M., Bradley, A., and
Karsenty, G. (1995) Genes Dev. 9, 2808–2820
15. Hogan, B. L. M. (1996) Genes Dev. 10, 1580–1594
16. Graff, J. M. (1997) Cell 89, 171–174
17. Katagiri, T., Yamaguchi, A., Komaki, M., Abe, E., Takahashi, N., Ikeda, T.,
Rosen, V., Wozney, J. M., Fujisawa, A., and Suda, T. (1994) J. Cell Biol. 127,
1755–1766
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